Overview

Prospective Study of TW in Treatment of IgAN With Asymptomatic Abnormal Urinalysis

Status:
Terminated
Trial end date:
2011-05-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to: 1. To evaluate the latest effects of TW for IgA nephropathy (IgAN) with asymptomatic abnormal urinalysis. 2. To evaluate the safety and tolerability of TW.
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Nanjing University School of Medicine
Criteria
Inclusion Criteria:

1. 18-60 years old but no requirement for gender

2. All well fit the Diagnostic Criteria for Primary IgAN and IgAN with asymptomatic
abnormal urinalysis

3. Informed consent is obtained from each research subject who agrees to conduct a
periodic follow-up according to the research arrangement

Exclusion Criteria:

1. Secondary IgA nephropathy, such as Henoch-Schönlein purpura nephritis, Lupus nephritis
and so on

2. Some secondary kidney diseases like diabetic nephropathy or other systemic diseases
which may effect the pathologic and physiological function of kidney like hypertension
and arteriosclerosis

3. Severe infection

4. Abnormality of liver function with glutamic pyruvic transaminase (GPT) or
glutamic-oxal(o)acetic transaminase (GOT) more than twice upper limit of normal

5. Women during pregnancy and lactation

6. Patients need to procreation lately

7. Patients treated with TW or ARB within 4 months